Market Overview

Cardiac Biomarker Market is projected to achieve a value of USD 13,370 Million in 2023, with a linear behavior in the market growth it is forecasted to achieve a value of USD 38,000 Million by 2033 with a CAGR of 11% during the forecast period 2023-2033.

Cardiac Biomarker are protein molecule that are released into the blood after heart damage or intense heart stress. These biomarkers act as a potential indication tool to find out the various cardiovascular diseases (CVD) such as myocardial infarction, acute coronary syndrome, cardiac ischemia and congestive heart failure. The test uses to determine the risk and condition of patients associate with such disease is Cardiac biomarker tests.

Cardiac Biomarkers tests are performed when the patient suffers from chest pain. Troponin, creatine kinase-muscle/brain (CK-MB), B-type natriuretic peptide (BNP), high-sensitivity C-reactive protein (hs-CRP), this are the cardiac biomarkers that are tested for cardiovascular diseases. Myocardial muscle creatine kinase (CK-MB), troponin I and T, myoglobin, brain natriuretic peptide (BNPs), ischemia modified albumin (IMA), these are the Cardiac biomarkers that are widely used as an integrated diagnostic approach for cardiovascular diseases., thereby providing a smoother scenario for overall Cardiac biomarker market growth.

Market Scope

Report Attributes	Description
Market Size in 2022	USD 13,870 Million
Market Forecast in 2033	USD 38,000 Million
CAGR % 2023-2033	11%
Base Year	2022
Historic Data	2016-2022
Forecast Period	2023-2033
Report USP	Production, Consumption, company share, company heatmap, company production capacity, growth factors and more
Segments Covered	Type, Application and End-user
Regional Scope	North America, Europe, APAC, South America and Middle East and Africa
Country Scope	U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria
Key Companies	F. Hoffmann-La Roche AG, Abbott, Siemens AG, Creative Diagnostics, Beckman Coulter, Inc., Thermo Fisher Scientific Inc., bioMérieux SA Others

 

 Market Dynamics

Cardiac biomarker market is driven by many factors such as the rising burden of cardiovascular diseases, increasing research and development investments and technological advances in cardiac biomarkers. For instance, according to the British Heart Foundation data published in January 2022 reported that in 2021, the most common heart conditions affected globally were ischemic heart disease, peripheral arterial (vascular) disease (110 million), stroke (100 million), and atrial fibrillation (60 million).

Furthermore, the technologically advanced cardiac biomarkers launched by various market players is also anticipated to enhance the growth the Cardiac biomarker market. For instance, in April 2021, Roche launched a series of five new intended uses for two key cardiac biomarkers using the Elecsys technology, i.e., N-terminal pro-brain natriuretic peptide test (NT-proBNP) and high-sensitive cardiac troponin T (cTnT-hs).

COVID-19 pandemic impact is expected to remain positive for the cardiac biomarkers testing industry. Increasing the number of patients having preexisting history of cardiovascular diseases with COVID 19. As these patients with existing medical conditions like cardiovascular disease suffering from COVID-19 are more heart attack. Moreover, it was found that the troponil level is higher significant in COVID 19 patients who die or critical in condition.

Moreover, emerging markets such as India and china offers a significant growth in cardiac diagnosing market. For Instance, According to IHA (Indian Heart Association) 2019, India accountable for 60% of global heart disease burden, among them 50% of all heart attacks in Indian men under the age of 50 years. The increasing burden of cardiovascular diseases in growing countries which drive the demand for early disease diagnosis increasing the adoption of cardiac marker testing products.

Market Type Analysis

The cardiac biomarker market is Categories into Troponin, CK-MB, Myoglobin, BNP and NT-proBNP. The Troponin segment accounts for the largest share of around 35% of the market in 2022. The significant growth can be attributed to factors such as specificity, diagnostic efficiency, and accurate predictive detection of cardiac events when compared to other tests. The increasing prevalence of MI (myocardial infarction) and stroke all over the world further boosts market growth

BNP and NT-proBNP segment is expected to grow rapidly due to its significantly use in detecting heart damage and stress. Companies are entering the market with this test to generate more  sale. For instance, in June 2022, LumiraDx Limited announced the diversification of its portfolio with a CE Mark for its D-Dimer test and NT-proBNP test. The commercialization of the latter is projected by the end of 2022, which is expected to facilitate clinical decision-making.

Market Application Analysis

By Application, the Cardiac biomarker market is Categories into Acute Coronary Syndrome, Myocardial Infarction (MI). The Myocardial Infarction segment accounts for the largest share of around 53% of the market in 2022.

Myocardial infarction is a stage of dyeing heart muscles due a lack of oxygen-rich blood flow to the heart muscle. I biomarkers and Cardiac Troponin T tests have emerged as the prime diagnostic methods for diagnosing the disease.

Market End User Analysis

By End-user, the Cardiac biomarker market is Categories into Hospital, speciality Clinics. The Hospital segment accounts for the largest share of around 56% of the market in 2022. Rising investment in healthcare and increasing hospital facility in developed and developing country are major factor to drive the segment. Increasing prevalence of cardiovascular diseases and COVID-19 is one more additional factor which helps to dominate the segment.

However, specialty clinics and number of other services like modern testing labs and ambulatory services in developing countries are anticipated to drive the Cardiac Biomarker Market.

Market Regional Analysis

North America dominate the Cardiac Biomarker market with the highest revenue generating market with share of more than 42%. Well established healthcare facility, availability of services and products, high expenditure on R&D are the key driving factor of the region. For instance, according to the American College of Cardiology Foundation, in 2019 it is estimated that about 1.05 million patients were suffering from coronary disorders in the United States alone.

Asia-Pacific is expected to expand the higher growth with highest CAGR in forecasted year. The factors behind that are increasing investment in healthcare sector, increasing awareness about the cardiovascular diseases, after COVID19 increasing the cardiac testing facility in the region. For instance, in January 2023, Cipla Inc, an Indian multinational pharmaceutical company, launched a diagnostic device called Cippoint, which offers a point-of-care testing solution for various health conditions

Moreover, Europe is the fastest growing Cardiac Biomarker market in forecasting year. Rising prevalence of acute coronary syndrome and myocardial infarction leading to the increasing demand to improve diagnostic facility, government funding for research and targeted diseases and healthcare expenditure.

Latin America and Middle East & Africa are expected to grow at a moderate level because of slower adoption of technologically advanced solutions and lack of awareness among the population towards tests for cardiac biomarker industry.

Competitive Analysis

The Cardiac Biomarker market is dominated by a few large companies, such as F. Hoffmann-La Roche AG, Abbott, Siemens AG, Creative Diagnostics, Beckman Coulter, Inc., Thermo Fisher Scientific Inc., bioMérieux SA, Others.

There are some of the key trends that are shaping the competitive landscape of the Cardiac Biomarker market.

April 2021 –Siemens AG. announced that they received CE Mark approval for their point-of-care Atellica VTLiPatient-Side Immunoassay Analyzer, a high sensitivity troponin I test. The approved device detects protein biomarkers for acute myocardial infraction.

April 2021 – F. Hoffmann-La Roche Ltd announced the launch of five new applications for their key cardiac biomarkers in combination with their Elecsys technology. These biomarkers have been proved to be successful managing cardiovascular diseases and can help clinicians to diagnose heart attacks and manage heart failures in patients.

Sept 2019 -Abbott Laboratories received FDA approval for the ARCHITECT STAT High sensitivity Troponin-I blood test used in the diagnosis of myocardial infraction.

By Type

·         Troponin

·         CK-MB

·         Myoglobin

·         BNP and NT-proBNP

By Application

·         Acute Coronary Syndrome

·         Myocardial Infarction

By End-User

·         Hospital

·         speciality Clinics

1.      Global Cardiac Biomarkers Market Introduction and Market Overview

1.1.    Objectives of the Study

1.2.    Global Cardiac Biomarkers Market Scope and Market Estimation

1.2.1. Global Cardiac Biomarkers Overall Market Size, Revenue (US$ Mn), Market CAGR (%), Market forecast (2023 - 2033)

1.2.2. Global Cardiac Biomarkers Market Revenue Share (%) and Growth Rate (Y-o-Y) from 2019 - 2033

1.3.    Market Segmentation

1.3.1. Component of Global Cardiac Biomarkers Market

1.3.2. Technology of Global Cardiac Biomarkers Market

1.3.3. End-user of Global Cardiac Biomarkers Market

1.3.4. Region of Global Cardiac Biomarkers Market

2.      Executive Summary

2.1.    Global Cardiac Biomarkers Market Industry Trends under COVID-19 Outbreak

2.1.1. Global COVID-19 Status Overview

2.1.2. Influence of COVID-19 Outbreak on Global Cardiac Biomarkers Market Industry Development

2.2.    Market Dynamics

2.2.1. Drivers

2.2.2. Limitations

2.2.3. Opportunities

2.2.4. Impact Analysis of Drivers and Restraints

2.3.    Pricing Trends Analysis & Average Selling Prices (ASPs)

2.4.    Key Mergers & Acquisitions, Expansions, JVs, Funding / VCs, etc.

2.5.    Porter’s Five Forces Analysis

2.5.1. Bargaining Power of Suppliers

2.5.2. Bargaining Power of Buyers

2.5.3. Threat of Substitutes

2.5.4. Threat of New Entrants

2.5.5. Competitive Rivalry

2.6.    Value Chain / Ecosystem Analysis

2.7.    Russia-Ukraine War Impacts Analysis

2.8.    Economic Downturn Analysis

2.9.      Market Investment Opportunity Analysis (Top Investment Pockets), By Segments & By Region

3.      Global Cardiac Biomarkers Market Estimates & Historical Trend Analysis (2019 - 2022)

4.      Global Cardiac Biomarkers Market Estimates & Forecast Trend Analysis, by TYPE

4.1.    Global Cardiac Biomarkers Market Revenue (US$ Mn) Estimates and Forecasts, by TYPE, 2019 to 2033

4.1.1. Hardware

4.1.2. Software

4.1.2.1.              Device Management

4.1.2.2.              Signal Processing

4.1.3. Services

5.      Global Cardiac Biomarkers Market Estimates & Forecast Trend Analysis, by Application

5.1.    Global Cardiac Biomarkers Market Revenue (US$ Mn) Estimates and Forecasts, by Application, 2019 to 2033

5.1.1. 2G

5.1.2. 3G

5.1.3. 4G

5.1.4. LTE-M

5.1.5. NB-LTE-M

5.1.6. NB-IoT

5.1.7. 5G

6.      Global Cardiac Biomarkers Market Estimates & Forecast Trend Analysis, by End-user

6.1.    Global Cardiac Biomarkers Market Revenue (US$ Mn) Estimates and Forecasts, by End-user, 2019 to 2033

6.1.1. Agriculture

6.1.2. Automotive & Transportation

6.1.3. Consumer Electronics

6.1.4. Energy

6.1.5. Environment Monitoring

6.1.6. Healthcare

6.1.7. Retail

6.1.8. Smart Cities

6.1.9. Others

7.      Global Cardiac Biomarkers Market Estimates & Forecast Trend Analysis, by Region

7.1.    Global Cardiac Biomarkers Market Revenue (US$ Mn) Estimates and Forecasts, by Region, 2019 to 2033

7.1.1. North America

7.1.2. Europe

7.1.3. Asia Pacific

7.1.4. Middle East & Africa

7.1.5. South America

8.      North America Cardiac Biomarkers Market: Estimates & Forecast Trend Analysis

8.1.    North America Cardiac Biomarkers Market Assessments & Key Findings

8.1.1. North America Cardiac Biomarkers Market Introduction

8.1.2. North America Cardiac Biomarkers Market Size Estimates and Forecast (US$ Million) (2019 – 2033)

8.1.2.1.   By TYPE

8.1.2.2.   By Application

8.1.2.3.   By End-user

8.1.2.4.   By Country

8.1.2.4.1.     The U.S.

8.1.2.4.2.     Canada

8.1.2.4.3.     Mexico

9.      Europe Cardiac Biomarkers Market: Estimates & Forecast Trend Analysis

9.1.    Europe Cardiac Biomarkers Market Assessments & Key Findings

9.1.1. Europe Cardiac Biomarkers Market Introduction

9.1.2. Europe Cardiac Biomarkers Market Size Estimates and Forecast (US$ Million) (2019 – 2033)

9.1.2.1.   By TYPE

9.1.2.2.   By Application

9.1.2.3.   By End-user

9.1.2.4.        By Country

9.1.2.4.1.     Germany

9.1.2.4.2.     U.K.

9.1.2.4.3.     France

9.1.2.4.4.     Italy

9.1.2.4.5.     Spain

9.1.2.4.6.     Russia

9.1.2.4.7.     Rest of Europe

10.  Asia Pacific Cardiac Biomarkers Market: Estimates & Forecast Trend Analysis

10.1.  Asia Pacific Market Assessments & Key Findings

10.1.1.   Asia Pacific Cardiac Biomarkers Market Introduction

10.1.2.   Asia Pacific Cardiac Biomarkers Market Size Estimates and Forecast (US$ Million) (2019 – 2033)

10.1.2.1.    By TYPE

10.1.2.2.    By Application

10.1.2.3.    By End-user

10.1.2.4.    By Country

10.1.2.4.1. China

10.1.2.4.2. Japan

10.1.2.4.3. India

10.1.2.4.4. Australia

10.1.2.4.5. South Korea

10.1.2.4.6. ASEAN

10.1.2.4.7. Rest of Asia Pacific

11.  Middle East & Africa Cardiac Biomarkers Market: Estimates & Forecast Trend Analysis

11.1.  Middle East & Africa Market Assessments & Key Findings

11.1.1.   Middle East & Africa Cardiac Biomarkers Market Introduction

11.1.2.   Middle East & Africa Cardiac Biomarkers Market Size Estimates and Forecast (US$ Million) (2019 – 2033)

11.1.2.1.    By TYPE

11.1.2.2.    By Application

11.1.2.3.    By End-user

11.1.2.4.    By Country

11.1.2.4.1. U.A.E.

11.1.2.4.2. Saudi Arabia

11.1.2.4.3. Egypt

11.1.2.4.4. South Africa

11.1.2.4.5. Rest of Middle East & Africa

12.  South America Cardiac Biomarkers Market: Estimates & Forecast Trend Analysis

12.1.  South America Market Assessments & Key Findings

12.1.1.   South America Cardiac Biomarkers Market Introduction

12.1.2.   South America Cardiac Biomarkers Market Size Estimates and Forecast (US$ Million) (2019 – 2033)

12.1.2.1.    By TYPE

12.1.2.2.    By Application

12.1.2.3.    By End-user

12.1.2.4.    By Country

12.1.2.4.1. Brazil

12.1.2.4.2. Argentina

12.1.2.4.3. Colombia

12.1.2.4.4. Rest of South America

13.  Competition Landscape

13.1.  Global Cardiac Biomarkers Market Competition Matrix & Benchmarking, by Leading Players / Innovators / Emerging Players / New Entrants

13.2.  Global Cardiac Biomarkers Market Competition White Space Analysis, By End-user

13.3.  Global Cardiac Biomarkers Market Competition Heat Map Analysis, By End-user

13.4.  Global Cardiac Biomarkers Market Concentration & Company Market Shares (%) Analysis, 2022

14.  Company Profiles

14.1.                     Qualcomm Inc.

14.1.1.   Company Overview & Key Stats

14.1.2.   Financial Performance & KPIs

14.1.3.   Product Portfolio

14.1.4.   Business Strategy & Recent Developments

* Similar details would be provided for all the players mentioned below 

14.2.      Commsolid GmbH

14.3.      Gemalto NV

14.4.      MediaTek Inc.

14.5.      Mistbase Communication System

14.6.      Sequans Communications

14.7.      Sierra Wireless

14.8.      Telit Communications PLC

14.9.      Ericsson

14.10.  Texas Instruments

14.11.  Thales Group

14.12.  ZTE Corporation

14.13.  U-Blox Holding AG

14.14.  Others**

15.  Research Methodology

15.1.  External Transportations / Databases

15.2.  Internal Proprietary Database

15.3.  Primary Research

15.4.  Secondary Research

15.5.  Assumptions

15.6.  Limitations

15.7.  Report FAQs

16.  Research Findings & Conclusion

Quality Assurance Process

1. We Market Research’s Quality Assurance program strives to deliver superior value to our clients.

We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.

Market Research Process

We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.

To mitigate risks that can impact project success, we deploy the follow project delivery best practices:

• Project kickoff meeting with client
• Conduct frequent client communications
• Form project steering committee
• Assign a senior SR executive as QA Executive
• Conduct internal editorial & quality reviews of project deliverables
• Certify project staff in SR methodologies & standards
• Monitor client satisfaction
• Monitor realized value post-project

Case Study- Automotive Sector

One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).

Solution

The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research

The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.

Market Estimates and Forecast

In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.

Case Study- ICT Sector

Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.

Business Solution

An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.

Conclusion

The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.